Century Therapeutics, Inc.
IPSC
$0.51
-$0.02-3.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 12,667.72% | 1,457.09% | 434.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 12,667.72% | 1,457.09% | 434.46% |
| Cost of Revenue | -17.27% | -1.33% | 13.49% | 31.75% | 19.48% |
| Gross Profit | 14.79% | -1.55% | 465.97% | -14.41% | -16.77% |
| SG&A Expenses | -18.16% | -6.03% | -3.83% | 6.08% | -7.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.48% | -2.43% | 8.78% | 24.61% | 11.98% |
| Operating Income | 15.60% | 0.26% | 336.92% | -12.07% | -10.00% |
| Income Before Tax | -10.21% | -4.35% | 372.83% | 14.83% | 2.78% |
| Income Tax Expenses | -- | -- | -- | 304.37% | -101.35% |
| Earnings from Continuing Operations | -10.24% | -4.27% | 372.82% | 8.44% | 4.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.24% | -4.27% | 372.82% | 8.44% | 4.57% |
| EBIT | 15.60% | 0.26% | 336.92% | -12.07% | -10.00% |
| EBITDA | 16.70% | -0.54% | 375.60% | -14.52% | -11.37% |
| EPS Basic | -8.00% | 0.74% | 297.56% | 35.69% | 33.03% |
| Normalized Basic EPS | 13.28% | 0.67% | 297.62% | 18.87% | 22.05% |
| EPS Diluted | -8.11% | 0.03% | 297.56% | 35.69% | 32.78% |
| Normalized Diluted EPS | 13.28% | 0.67% | 297.44% | 18.87% | 22.05% |
| Average Basic Shares Outstanding | 2.08% | 5.05% | 38.08% | 42.37% | 42.48% |
| Average Diluted Shares Outstanding | 2.08% | 5.05% | 38.21% | 42.37% | 42.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |